Pharmaceutical - Xofigo, Oncology

Filter

Current filters:

XofigoOncology

Popular Filters

Bayer boasts strong R&D pipeline and growth prospects

03-12-2014

German pharma major Bayer gave a spirited presentation of its pipeline candidates in both pharma and…

AdempasBayerEyleaFinancialHematologyOncologyOphthalmicsPharmaceuticalResearchStivargaXareltoXofigo

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

UK’s NICE unable to give the go ahead to new prostate cancer drug Xofigo

24-03-2014

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued new draft…

BayerNorthern EuropeOncologyPharmaceuticalPricingRegulationUKXofigo

Way clear for Bayer to complete Algeta acquisition

26-02-2014

The way is now clear for Germany’s Bayer to acquire Norwegian pharmaceutical company Algeta, under…

AlgetaBayerMergers & AcquisitionsOncologyPharmaceuticalXofigo

Bayer confirms plans to acquire Norway’s Algeta

Bayer confirms plans to acquire Norway’s Algeta

19-12-2013

German drugs and chemicals major Bayer has officially announced its intention to acquire Norwegian pharmaceutical…

AlgetaBayerGermanyMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

Norway’s Algeta confirms takeover bid approach from Bayer

Norway’s Algeta confirms takeover bid approach from Bayer

26-11-2013

In response to recent media commentary, the board of directors of Norway’s Algeta this morning confirmed…

AlgetaBayerMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

EU approval for Bayer’s prostate cancer drug Xofigo

EU approval for Bayer’s prostate cancer drug Xofigo

15-11-2013

The European Commission has granted marketing authorization for German drug and chemical major Bayer’s…

AlgetaBayerEuropeOncologyPharmaceuticalRegulationXofigo

EMA unit backs approval of Bayer's radium-233

EMA unit backs approval of Bayer's radium-233

20-09-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AlgetaBayerEuropeOncologyPharmaceuticalradium-223 dichlorideRegulationXofigo

Fast FDA approval for Bayer's new drug for advanced prostate cancer, Xofigo

16-05-2013

The US Food and Drug Administration yesterday (May 15) approved Xofigo (radium Ra 223 dichloride, initially…

AlgetaAstellas PharmaBayerNorth AmericaOncologyPharmaceuticalRegulationXofigo

Back to top